KYPROLIS — Total revenues
Amgen KYPROLIS — Total revenues decreased by 6.0% to $330.00M in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 1.9%, from $324.00M to $330.00M. Over 4 years (FY 2021 to FY 2025), KYPROLIS — Total revenues shows an upward trend with a 6.2% CAGR. This decline may warrant attention — for this metric, higher values are generally preferred.
Analysis
How to read this metric
An increase indicates growing market share or successful clinical adoption in the multiple myeloma space, while a decrease may signal increased competition from generics, biosimilars, or newer therapeutic classes.
Detailed definition
This metric represents the total global net sales generated from the commercialization of the proteasome inhibitor thera...
Peer comparison
Comparable to revenue metrics for specialized oncology products or targeted therapies in the portfolios of large-cap biopharmaceutical peers.
amgn_segment_kyprolis_carfilzomib_total_revenuesHistorical Data
| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $280.00M | $293.00M | $284.00M | $287.00M | $317.00M | $318.00M | $325.00M | $358.00M | $346.00M | $349.00M | $350.00M | $376.00M | $377.00M | $378.00M | $372.00M | $324.00M | $378.00M | $359.00M | $351.00M | $330.00M |
| QoQ Change | — | +4.6% | -3.1% | +1.1% | +10.5% | +0.3% | +2.2% | +10.2% | -3.4% | +0.9% | +0.3% | +7.4% | +0.3% | +0.3% | -1.6% | -12.9% | +16.7% | -5.0% | -2.2% | -6.0% |
| YoY Change | — | — | — | — | +13.2% | +8.5% | +14.4% | +24.7% | +9.1% | +9.7% | +7.7% | +5.0% | +9.0% | +8.3% | +6.3% | -13.8% | +0.3% | -5.0% | -5.6% | +1.9% |
Similar Metrics at Other Companies
Frequently Asked Questions
- What is Amgen's kyprolis — total revenues?
- Amgen (AMGN) reported kyprolis — total revenues of $330.00M in Q1 2026.
- How has Amgen's kyprolis — total revenues changed year-over-year?
- Amgen's kyprolis — total revenues increased by 1.9% year-over-year, from $324.00M to $330.00M.
- What is the long-term trend for Amgen's kyprolis — total revenues?
- Over 4 years (2021 to 2025), Amgen's kyprolis — total revenues has grown at a 6.2% compound annual growth rate (CAGR), from $1.11B to $1.41B.
- What does kyprolis — total revenues mean?
- The total revenue generated from the sales of the oncology drug Kyprolis.